<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Long-term outcome, after first line intensified high-dose sequential (i-HDS) chemotherapy, was evaluated in 46 patients, aged &lt; or =65 years, with advanced low-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Seventeen patients had small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>), 29 had follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), 10 of them with histologic transformation </plain></SENT>
<SENT sid="2" pm="."><plain>I-HDS included: (1) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> debulking, by 2 APO+2 DHAP courses; (2) sequential administration of high-dose (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">hd</z:e>) <z:chebi fb="0" ids="4911">etoposide</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, followed by peripheral blood progenitor cell (PBPC) harvest; (3) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">hd</z:e>-<z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> + melphalan with PBPC autograft </plain></SENT>
<SENT sid="3" pm="."><plain>Ten FL patients had their PBPC immunologically purged ex vivo </plain></SENT>
<SENT sid="4" pm="."><plain>There were two treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo>; five FL patients had short-lasting response followed by disease progression, five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e> reached a stable PR; overall, 34 patients (74%) reached CR </plain></SENT>
<SENT sid="5" pm="."><plain>At a median follow-up of 4.3 years, the estimated 9-year OS and EFS were 84% and 45%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>No significant differences were observed in the OS among patients at low, intermediate or high IPI score, with an estimated OS projection of 95%, 78%, and 75%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>FL had longer survival without evidence of <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> (9-year EFS: 59%) as compared to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e> patients (8.8-year EFS: 17%); however, both groups had prolonged survival and no need of salvage treatment, as shown by the time to disease progression curve, projected to 66% and 62% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e> and FL, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The results indicate that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">hd</z:e>-approach in low-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo>: (1) is associated with longer progression-free survival as compared to conventional therapies; (2) may imply higher <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass reduction in FL as compared to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e> patients; (3) offers long life expectancy, with potential survival benefits at least for patients at intermediate/high IPI score </plain></SENT>
</text></document>